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SIR,-May we, through the courtesy of
your columns, inform surgeons, radio-
therapists and other interested doctors of a
new clinical trial which will shortly be
launched?
This will be a nationwide study, supported
by the Cancer Research Campaign, in which
the main objective will be to compare two
types of treatment. Patients will be prospec-
tively randomized to undergo either simple
mastectomy with axillary node sampling and
postoperative radiotherapy, or local excision
oftumour ("lumpectomy"), also with axillary
nodes sampling and radical radiotherapy
treatment. This study protocol provides for
radiotherapy in similar dosage to both
groups of patients, so that the surgical treat-
ment will be the only variable. Although the
survival of these patients will of course be of
the greatest importance, the trial design will
also allow us to assess the local recurrence
rate, the cosmetic results of treatment, and
(in a selected group of patients) the psycho-
logical sequelae of the two methods of
treatment.
In order for this study to have the power
to discriminate between small but possibly
important differences in these two methods
of treatment, it will be necessary to include
a large number ofpatients. We hope to study
some 2000 women. We therefore invite all
interested clinicians to participate in this
trial and if you wish to receive a protocol,
please write to Mrs J. Houghton at the
address below.
Our motivation has been a genuine uncer-
tainty on the part of this Working Party as
to whether local excision with radical radio-
therapy offers a realistic and safe alternative
to mastectomy, and we feel that this study
should make a major contribution towards
answering this critical question.
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POSTCHEMOTHERAPY STAGING LAPAROTOMY IN HODGKIN'S
DISEASE
SIR.-Barr et al. (1982) recently concluded
in this journal that a postchemotherapy
staging laparotomy (SL) in Hodgkin's disease
is not recommended either for patients in
clinical remission or for patients with
evidence ofrelapsed disease, regardless ofthe
stage ofdisease.
We agree that SL is of little value for
carefully-staged patients with CS I and
II disease having been initially treated
with polychemotherapy instead of radio-
therapy.
On the other side our own experience
supports the conception that SL might be
justified furthermore in patients with CS IIIB
and IVB disease to detect residual tumor not
sufficiently eradicated by polychemotherapy
(Sutcliffe & Stansfield, 1978).
During the 10-year period 1972 to 1981
56/88 patients (64%) with stage IIIB (n=46)
or IVB (n=10) have had a postprimary
staging laparotomy (PPSL) (Kuse et al., 1979)
within 2 months after the completion of at
least 6 cycles of COPP- or COPP+ABVD-
polychemotherapy. The median age was 32
and the range, 15-60 years. In 27 cases PPSL